Cargando…
High Dose of Pegylated Interferon for the Treatment of Chronic Hepatitis B in Children Infected With Genotype C
Chronic hepatitis B virus (HBV) genotype C infection is unlikely to show a good response to interferon (IFN). However, it is unknown whether a high dose of pegylated IFN (PEG-IFN) treatment would be effective for hepatitis B e antigen (HBeAg)-positive children with chronic HBV genotype C infection....
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191545/ https://www.ncbi.nlm.nih.gov/pubmed/37206604 http://dx.doi.org/10.1097/PG9.0000000000000005 |
_version_ | 1785043484582871040 |
---|---|
author | Komatsu, Haruki Inui, Ayano Yoshio, Sachiyo Kanto, Tatsuya Umetsu, Shuichiro Tsunoda, Tomoyuki Fujisawa, Tomoo |
author_facet | Komatsu, Haruki Inui, Ayano Yoshio, Sachiyo Kanto, Tatsuya Umetsu, Shuichiro Tsunoda, Tomoyuki Fujisawa, Tomoo |
author_sort | Komatsu, Haruki |
collection | PubMed |
description | Chronic hepatitis B virus (HBV) genotype C infection is unlikely to show a good response to interferon (IFN). However, it is unknown whether a high dose of pegylated IFN (PEG-IFN) treatment would be effective for hepatitis B e antigen (HBeAg)-positive children with chronic HBV genotype C infection. METHODS: HBeAg-positive children and adolescents with chronic HBV genotype C infection were eligible for this study. To increase the dose of PEG-IFN, all patients received PEG-IFN-α-2a (180 μg) without dose adjustment on the basis of body surface area for 48 weeks and were followed up for 24 weeks after the completion of treatment. RESULTS: Thirteen patients (median age, 9 years) were enrolled prospectively for this study. One patient dropped out, and the remaining 12 patients were evaluated. Of the 12 patients, 11 received PEG-IFN of 180 μg/1.73 m(2) or more (median, 287 μg/1.73 m(2)). Eight (67%) experienced HBeAg seroconversion, and 1 (8%) achieved hepatitis B surface antigen (HBsAg) loss at the end of follow-up. There was a significant difference in the decrease of hepatitis B surface antigen levels from the baseline to week 24 of treatment between the responders and the nonresponders. Serum cytokines and chemokines were measured in 10 patients. The levels of C-X-C motif chemokine ligand 9, 10, 11, and 13 in the responders tended to be higher than those in the nonresponders during the first 24 weeks of treatment. CONCLUSIONS: A high dose of PEG-IFN treatment was effective and safe. A decrease in the hepatitis B surface antigen level from baseline to week 24 of treatment might be a predictor of HBeAg seroconversion. |
format | Online Article Text |
id | pubmed-10191545 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101915452023-05-18 High Dose of Pegylated Interferon for the Treatment of Chronic Hepatitis B in Children Infected With Genotype C Komatsu, Haruki Inui, Ayano Yoshio, Sachiyo Kanto, Tatsuya Umetsu, Shuichiro Tsunoda, Tomoyuki Fujisawa, Tomoo JPGN Rep Original Article Chronic hepatitis B virus (HBV) genotype C infection is unlikely to show a good response to interferon (IFN). However, it is unknown whether a high dose of pegylated IFN (PEG-IFN) treatment would be effective for hepatitis B e antigen (HBeAg)-positive children with chronic HBV genotype C infection. METHODS: HBeAg-positive children and adolescents with chronic HBV genotype C infection were eligible for this study. To increase the dose of PEG-IFN, all patients received PEG-IFN-α-2a (180 μg) without dose adjustment on the basis of body surface area for 48 weeks and were followed up for 24 weeks after the completion of treatment. RESULTS: Thirteen patients (median age, 9 years) were enrolled prospectively for this study. One patient dropped out, and the remaining 12 patients were evaluated. Of the 12 patients, 11 received PEG-IFN of 180 μg/1.73 m(2) or more (median, 287 μg/1.73 m(2)). Eight (67%) experienced HBeAg seroconversion, and 1 (8%) achieved hepatitis B surface antigen (HBsAg) loss at the end of follow-up. There was a significant difference in the decrease of hepatitis B surface antigen levels from the baseline to week 24 of treatment between the responders and the nonresponders. Serum cytokines and chemokines were measured in 10 patients. The levels of C-X-C motif chemokine ligand 9, 10, 11, and 13 in the responders tended to be higher than those in the nonresponders during the first 24 weeks of treatment. CONCLUSIONS: A high dose of PEG-IFN treatment was effective and safe. A decrease in the hepatitis B surface antigen level from baseline to week 24 of treatment might be a predictor of HBeAg seroconversion. Lippincott Williams & Wilkins, Inc. 2020-08-19 /pmc/articles/PMC10191545/ /pubmed/37206604 http://dx.doi.org/10.1097/PG9.0000000000000005 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer on behalf of European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Komatsu, Haruki Inui, Ayano Yoshio, Sachiyo Kanto, Tatsuya Umetsu, Shuichiro Tsunoda, Tomoyuki Fujisawa, Tomoo High Dose of Pegylated Interferon for the Treatment of Chronic Hepatitis B in Children Infected With Genotype C |
title | High Dose of Pegylated Interferon for the Treatment of Chronic Hepatitis B in Children Infected With Genotype C |
title_full | High Dose of Pegylated Interferon for the Treatment of Chronic Hepatitis B in Children Infected With Genotype C |
title_fullStr | High Dose of Pegylated Interferon for the Treatment of Chronic Hepatitis B in Children Infected With Genotype C |
title_full_unstemmed | High Dose of Pegylated Interferon for the Treatment of Chronic Hepatitis B in Children Infected With Genotype C |
title_short | High Dose of Pegylated Interferon for the Treatment of Chronic Hepatitis B in Children Infected With Genotype C |
title_sort | high dose of pegylated interferon for the treatment of chronic hepatitis b in children infected with genotype c |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191545/ https://www.ncbi.nlm.nih.gov/pubmed/37206604 http://dx.doi.org/10.1097/PG9.0000000000000005 |
work_keys_str_mv | AT komatsuharuki highdoseofpegylatedinterferonforthetreatmentofchronichepatitisbinchildreninfectedwithgenotypec AT inuiayano highdoseofpegylatedinterferonforthetreatmentofchronichepatitisbinchildreninfectedwithgenotypec AT yoshiosachiyo highdoseofpegylatedinterferonforthetreatmentofchronichepatitisbinchildreninfectedwithgenotypec AT kantotatsuya highdoseofpegylatedinterferonforthetreatmentofchronichepatitisbinchildreninfectedwithgenotypec AT umetsushuichiro highdoseofpegylatedinterferonforthetreatmentofchronichepatitisbinchildreninfectedwithgenotypec AT tsunodatomoyuki highdoseofpegylatedinterferonforthetreatmentofchronichepatitisbinchildreninfectedwithgenotypec AT fujisawatomoo highdoseofpegylatedinterferonforthetreatmentofchronichepatitisbinchildreninfectedwithgenotypec |